Articles and Videos
The Potential of Cannabinoids in the Treatment of Alzheimer’s Disease
InMed’s INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Promising early studies demonstrate INM-901’s neuroprotective effects and an ability...
Benzinga Live Panel Discussion – Transforming the CPG Landscape: Why Rare Cannabinoids Ingredients are the Next Big Thing
Jerry Griffin, VP of Sales and Marketing at BayMedica, InMed's subsidiary, joins this live panel discussion "Transforming the CPG Landscape: Why Rare Cannabinoids Ingredients are...
Podcast: Dr. Shane Johnson is guest on The Water Tower Hour (Live Recording from Benzinga Conference)
Dr. Shane Johnson, GM of BayMedica, InMed’s subsidiary, is a guest on The Water Tower Hour podcast. Host Jesse Redmond, Senior Analyst at Water Tower...
Source:
The Water Tower Hour
What quality controls should be put in place to ensure consistency and purity of cannabinoids for CPG products?
Dr. Shane Johnson, GM of BayMedica, InMed's subsidiary, answers these questions: What is the minimum GMP standard that consumers should expect? What quality controls should...
What makes cannabinoids an interesting pharmaceutical target?
Dr. Shane Johnson, GM of BayMedica, InMed's subsidiary, answers these questions: What is the role of the endocannabinoid system? How do cannabinoids interact with the...
What is the difference between illegal synthetics and bioidentical synthesized cannabinoids?
Dr. Shane Johnson, GM of BayMedica, InMed's subsidiary, answers these questions: What are illegal synthetic cannabinoids? How are illegal synthetic cannabinoids different from bioidentical synthesized...
